Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
HYB 211-02-02 is specific for human NGAL, native and denatured forms. Crossreactivity to other species has not
been determined.
HYB 211-02-02 has been successfully used in Western blotting, ELISA and Immunohistochemistry procedures. HYB 211-02-02 reacts strongly with NGAL. Strong reaction is seen when tested in sandwich ELISA in combination with a polyclonal antibody against the antigen. In immunohistochemical staining of paraformaldehyde fixed
neutrophils HYB 211-02-02 recognizes NGAL. In western blotting HYB 211-02-02 reacts with NGAL in both reduced as
well as unreduced form.
The HYB 211-02-02 immunogen is human recombinant NGAL in monomer and dimer forms adsorbed to aluminum hydroxide gel.
NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL
NGAL (Neutrophil gelatinase-associated lipocalin, lipocalin 2, siderocalin and neutrophil lipocalin) is a 25 kDa glycosylated single chain monomer and member of the lipocalin family of proteins that bind and transport small lipophilic molecules. NGAL is released by activated neutrophils, can form dimers and small amounts of higher oligomers, and complexes with matrix metalloproteinase 9 (MMP-9, gelatinase B). Low level expression of NGAL in a variety of epithelia may be increased in inflammation or cancers. Expression of NGAL in the kidney is dramatically increased by ischemic or nephrotoxic kidney injury.
仅用于科研。不用于诊断过程。未经明确授权不得转售。